Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 2OTHER 1NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Myeloid 4Classical hematology 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 4Myelodysplastic Syndromes 4Primary Myelofibrosis 3Leukemia, Myeloid, Acute 2Anemia 2beta-Thalassemia 1Hematologic Neoplasms 1

Interventions

fludarabine 19Whole-Body Irradiation 18Cyclophosphamide 17fludarabine phosphate 16ruxolitinib 15Mycophenolic Acid 14Specimen Handling 13Tacrolimus 11Azacitidine 11Biopsy 10Peripheral Blood Stem Cell Transplantation 9Melphalan 9Cytarabine 9venetoclax 8Sirolimus 8Busulfan 8Stem Cell Transplantation 6Injections 6Granulocyte Colony-Stimulating Factor 6Daunorubicin 5Cyclosporine 5CPX-351 5luspatercept 4ivosidenib 4itacitinib 4fedratinib 4decitabine and cedazuridine drug combination 4Thiotepa 4Liposomes 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × luspatercept × 1 year × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT05732961 2026-05-05

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
6 enrolled
Classical hematologyMyeloid

Anemia, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT04717414 2025-07-10

INDEPENDENCE

Celgene

Phase 3 Active not recruiting
313 enrolled
Classical hematologyMyeloid

Anemia, Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡